IQVIA Holdings Inc logo

IQVIA Holdings Inc (IQV)

Market Closed
8 Apr, 20:00
NYSE NYSE
$
144. 49
-8.52
-5.57%
$
41.52B Market Cap
38.04 P/E Ratio
0% Div Yield
2,697,700 Volume
10.19 Eps
$ 153.01
Previous Close
Day Range
142.57 159.03
Year Range
142.57 252.88
Earnings results expected in 21 days

Summary

IQV closed today lower at $144.49, a decrease of 5.57% from yesterday's close, completing a monthly decrease of -18.33% or $32.43. Over the past 12 months, IQV stock lost -27.33%.
IQV is not paying dividends to its shareholders.
The last earnings report, released on Feb 12, 2025, exceeded the consensus estimates by 0.01%. On average, the company has fell short of earnings expectations by -0.92%, based on the last three reports. The next scheduled earnings report is due on Apr 30, 2025.
The stock of the company had never split.
The company's stock is traded on 10 different exchanges and in various currencies, with the primary listing on NYSE (USD).
Want to track IQV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

IQV Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.

IQVIA Holdings Inc Dividends

IQV is not paying dividends to its shareholders.

IQVIA Holdings Inc Earnings

30 Apr 2025 (21 Days) Date
-
Cons. EPS
-
EPS
12 Feb 2025 Date
3.11
Cons. EPS
3.12
EPS
31 Oct 2024 Date
2.81
Cons. EPS
2.84
EPS
30 Oct 2024 Date
2.81
Cons. EPS
-
EPS
30 Jul 2024 Date
2.57
Cons. EPS
-
EPS
IQV is not paying dividends to its shareholders.
30 Apr 2025 (21 Days) Date
-
Cons. EPS
-
EPS
12 Feb 2025 Date
3.11
Cons. EPS
3.12
EPS
31 Oct 2024 Date
2.81
Cons. EPS
2.84
EPS
30 Oct 2024 Date
2.81
Cons. EPS
-
EPS
30 Jul 2024 Date
2.57
Cons. EPS
-
EPS

IQVIA Holdings Inc (IQV) FAQ

What is the stock price today?

The current price is $144.49.

On which exchange is it traded?

IQVIA Holdings Inc is listed on NYSE.

What is its stock symbol?

The ticker symbol is IQV.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 41.52B.

What is the earnings per share?

The EPS is 0.

When is the next earnings date?

The next earnings report will release on Apr 30, 2025.

Has IQVIA Holdings Inc ever had a stock split?

No, there has never been a stock split.

IQVIA Holdings Inc Profile

Diagnostics & Research Industry
Healthcare Sector
Mr. Ari Bousbib CEO
NYSE Exchange
US46266C1053 ISIN
US Country
87,000 Employees
- Last Dividend
- Last Split
9 May 2013 IPO Date

Overview

IQVIA Holdings Inc. is a cutting-edge company providing a suite of analytics, technology solutions, and clinical research services tailored for the life sciences sector. Operating globally, including the Americas, Europe, Africa, and the Asia-Pacific regions, IQVIA stands at the forefront of facilitating healthcare advancements. The company is organized into three main segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions, catering to a diverse range of needs within the pharmaceutical, biotechnology, medical device and diagnostic, and consumer health industries. Originally known as Quintiles IMS Holdings, Inc., it underwent a rebranding to IQVIA Holdings Inc. in November 2017. With its headquarters in Durham, North Carolina, IQVIA continues to foster collaborations, including a notable partnership with argenx SE, to drive innovation and improve patient outcomes in healthcare.

Products and Services

  • Technology & Analytics Solutions
  • This segment offers a plethora of cloud-based applications coupled with implementation services designed explicitly for life sciences and healthcare providers. It helps in generating real-world evidence for healthcare decision-making and enhancing patient outcomes. Among these services are strategic and implementation consulting, encompassing advanced analytics and commercial processes outsourcing. Moreover, IQVIA provides critical metrics related to pharmaceutical sales, prescribing trends, medical treatments, and various promotional activities, not to mention detailed sales or prescribing data at different geographical levels.

  • Research & Development Solutions
  • This division supports the full spectrum of clinical trial and research development, including project management, clinical monitoring, and patient-centric solutions. It assists in strategic planning and design for clinical trials, central laboratory services, genomic, bioanalytical, ADME (Absorption, Distribution, Metabolism, and Excretion), discovery, and vaccine and biomarker laboratory services, thereby accelerating the journey from early-stage research to market-ready products.

  • Contract Sales & Medical Solutions
  • Focused on enhancing engagement with healthcare providers and patients, this segment delivers comprehensive services spanning from health care provider engagement to scientific strategy and medical affairs. These solutions aim to optimize interactions between the medical community and the industry to foster a deeper understanding and adoption of advanced healthcare solutions and treatments.

Contact Information

Address: 2400 Ellis Road, Durham, NC, United States, 27703
Phone: 919 998 2000